# 🫘 Hypertensive Nephropathy

## 🎯 The Big Picture

**"Hypertensive nephropathy"** (also called nephrosclerosis) is listed as the **second-leading cause of end-stage renal disease** in the U.S. — yet it is almost always a diagnosis of exclusion, rarely confirmed by biopsy.

The honest summary: **some of it is real, much of it is a label of convenience.** A real entity exists, but a large share of what we call "hypertensive nephropathy" is actually another kidney disease in which high blood pressure is a passenger, not the driver.

### ✅ What Is Real

- **Malignant nephrosclerosis** — severe, accelerated hypertension unambiguously injures the kidney
- **Benign arteriolar nephrosclerosis** — the near-universal vascular aging change of chronic hypertension

### ⚠️ What Is Over-Called

- Slowly progressive CKD labeled "hypertensive" with **no biopsy**
- Especially in Black patients, where **APOL1** and occult glomerular disease account for much of it

## 📊 Epidemiology: The \#2 Cause of ESRD

In the USRDS registry, hypertension is the second-most-common assigned cause of incident ESRD (approximately **28–30%**), behind diabetes (approximately 45–47%). But that number comes from a **checkbox** on the CMS-2728 form completed at dialysis start — filled in by the certifying clinician, usually without a biopsy, and defaulting to "hypertension" whenever there is CKD + high BP + no obvious alternative.

### 📈 The Dose-Response Signal

Klag's 16-year MRFIT follow-up of 332,544 men found a graded relationship between baseline BP and later ESRD — the strongest population-level evidence that BP is doing *something* causal.

### ⚖️ The Racial Disparity

ESRD incidence in Black Americans is roughly **3.8×** that of White Americans, and "hypertension" is the most common assigned cause — a pattern that pointed, eventually, to a genetic driver.

### 💡 Clinical Pearl

Treat the USRDS "hypertension" line as an **administrative category, not a pathological one.** Its size reflects diagnostic convenience and the absence of biopsy as much as any true disease burden. The *true* incidence of biopsy-provable, hypertension-caused kidney failure is unknown and certainly lower.

## 🧬 The APOL1 Story: Why the Diagnosis Is Often Wrong

This is the development that reshaped the field. Two coding variants (G1, G2) in the **APOL1** gene — common on African chromosomes, essentially absent from European ones — are strongly associated with FSGS and, critically, with kidney disease that had been *attributed to hypertension*.

### 🔬 Genovese 2010

APOL1 high-risk variants strongly associated with FSGS and hypertension-attributed ESKD — variants that protect against African sleeping sickness but raise kidney-disease risk.

### 📋 Parsa 2013 (AASK)

Among 693 Black patients with CKD **"attributed to hypertension,"** those with the high-risk genotype reached the renal endpoint far more often (58% vs 37%) — the label was masking a genetic FSGS-spectrum disease.

### ⚠️ Don't Stop the Workup at the Label

In a Black patient labeled "hypertensive nephrosclerosis" who has FSGS-range proteinuria, unexplained rapid decline, or a family history of kidney disease — APOL1 genotyping or a biopsy will frequently **reclassify the disease.** "Hypertensive nephropathy" should never be the end of the diagnostic story.

## 🔄 The Autoregulation Paradox

Here is the core question the mechanism has to answer: **if the afferent arteriole autoregulates, how does systemic pressure ever reach the glomerulus?**

Normally the kidney holds blood flow and pressure steady across a wide range (mean arterial pressure ≈ 80–160 mmHg) using two **preglomerular** mechanisms that sit *upstream* of the glomerulus:

### ⚡ Myogenic Response

The afferent arteriole constricts when wall tension rises. Fast, and the **dominant protector** against pressure.

### 🧪 Tubuloglomerular Feedback

The macula densa senses distal NaCl and adjusts afferent tone (via adenosine). Slower, fine-tuning.

Because these act upstream, they **buffer** the glomerulus from systemic pressure. So injury requires that this protection *fail* — and it can fail by exactly two routes:

Systemic Hypertension ↓ Is preglomerular autoregulation intact AND is BP below the ceiling? ✅ Yes — protected ↓ Afferent constriction buffers pressure\
Minimal glomerular injury\
Slow hyaline change over years **Route A**\
BP exceeds the ceiling ↓ Autoregulatory breakthrough\
Barotrauma, fibrinoid necrosis\
**Malignant nephrosclerosis** **Route B**\
Autoregulation impaired\
(CKD, diabetes, low nephron mass, APOL1) ↓ Pressure transmitted to glomerulus\
Glomerular hypertension & hyperfiltration\
FSGS-type injury, **linear with BP** ↓ All routes converge on progressive CKD and ESRD

### 💊 Why This Matters at the Bedside

In a patient whose autoregulation is **already impaired** (established CKD or diabetes), there is no preglomerular buffer left. Even *moderate* systemic BP is transmitted straight to the glomerulus — which is why BP must be lowered **into the normotensive range** to protect these kidneys.

It is also why **ACE inhibitors and ARBs are renoprotective beyond their systemic BP effect**: they dilate the *efferent* arteriole, lowering *intraglomerular* pressure specifically. In the impaired-autoregulation state, glomerular pressure is the real target and systemic BP is only a proxy for it.

## 🧱 Arteriolar Remodeling: What Reverses, What Doesn't

A common teaching point — "arteriolar hypertrophy causes the damage, and it remodels away with BP control" — is only half right. The pieces of the vascular response have **opposite** implications, and reversibility tracks the *histology*, not the blood pressure.

| Structural change | Nature | Reverses with BP control? |
|----|----|----|
| **Eutrophic / muscular remodeling** (same media, smaller lumen) | Adaptive, protective | **Yes** — best with RAAS blockade, *not* with beta-blockers at equal BP |
| **Hyaline arteriolosclerosis** (glassy protein insudation) | Degenerative | **No** — fixed; causes ischemia + loss of autoregulation |
| **Global glomerulosclerosis / interstitial fibrosis** | Scar | **No** — fixed |

### 💡 Clinical Pearl

The *muscular* thickening is largely **protective** — it raises upstream resistance and shields the glomerulus. The damage begins when it tips into **hyalinosis**, which is doubly bad: it narrows the lumen (ischemia) *and* turns the vessel into a rigid tube that loses its protective myogenic reflex, re-opening Route B. Schiffrin's human studies showed an ACE inhibitor normalized small-artery structure while a beta-blocker did not, despite equal BP.

## 🧅 Onion-Skinning vs Hyaline: Two Different Diseases

Two arteriolar patterns are frequently confused. Knowing which is which tells you the tempo and the differential.

| Feature | Hyaline arteriolosclerosis | Hyperplastic ("onion-skin") |
|----|----|----|
| Setting | Chronic "benign" HTN, diabetes, aging | Malignant / accelerated HTN |
| Histology | Homogeneous, glassy, acellular wall thickening | Concentric layered myointimal proliferation |
| Tempo | Years | Days to weeks |
| Companion lesion | Ischemic glomerular obsolescence | Fibrinoid necrosis, thrombosis |

### ⚠️ Onion-Skinning Is Not Specific to Hypertension

The concentric myointimal lesion is **shared with thrombotic microangiopathies** — scleroderma renal crisis, HUS/TTP, antiphospholipid-syndrome nephropathy, radiation nephropathy. When you see onion-skinning, "malignant hypertension" is a diagnosis of the *whole clinical picture* (severe BP, fibrinoid necrosis, retinopathy, LVH) — not of the arteriole in isolation. If the context doesn't fit primary hypertension, work up a **TMA**.

## 💊 Clinical Implications for BP Management

### 🎯 Target the Glomerulus

In established CKD/diabetes, lower BP into the normotensive range — the preglomerular buffer is gone, so every mmHg is transmitted downstream.

### 💊 Prefer RAAS Blockade

ACEi/ARBs lower intraglomerular pressure specifically and preferentially reverse the adaptive vascular remodeling — a benefit beyond BP numbers.

### 🔬 Keep Looking

Proteinuria, rapid decline, hematuria, or family history? The "hypertensive" label doesn't fit — consider APOL1, biopsy, or a glomerular cause.

### ♻️ Some Injury Recovers

In malignant hypertension, controlling BP below the critical threshold lets acute microvascular injury genuinely repair — some patients recover meaningful function months later.

## 🔑 Key Takeaways

1.  The 28–30% "hypertension" share of ESRD is an **administrative attribution**, not a verified pathological incidence.
2.  It is substantially a **garbage-bag term** — especially in Black patients, where APOL1 and occult glomerular disease account for much of it — but a real core exists (malignant nephrosclerosis always; benign nephrosclerosis often).
3.  The afferent arteriole **does** protect the glomerulus. Injury requires either exceeding the ceiling (malignant) or losing autoregulation (CKD/diabetes/APOL1).
4.  Muscular remodeling is **protective and reversible** (RAAS \> beta-blocker); hyalinosis and glomerulosclerosis are **fixed scar**.
5.  Onion-skinning signals malignant HTN — but always consider the **TMA differential**.

## 📚 Key References

1.  Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. *JAMA.* 1997;277(16):1293–1298. [PMID: 9109467](https://pubmed.ncbi.nlm.nih.gov/9109467/)
2.  Meyrier A. Nephrosclerosis: a term in quest of a disease. *Nephron.* 2015;129(4):276–282. [PMID: 25871843](https://pubmed.ncbi.nlm.nih.gov/25871843/)
3.  Fogo A, Breyer JA, Smith MC, et al; AASK Pilot. Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans. *Kidney Int.* 1997;51(1):244–252. [PMID: 8995739](https://pubmed.ncbi.nlm.nih.gov/8995739/)
4.  Genovese G, Friedman DJ, Ross MD, et al. Association of trypanolytic ApoL1 variants with kidney disease in African Americans. *Science.* 2010;329(5993):841–845. [PMID: 20647424](https://pubmed.ncbi.nlm.nih.gov/20647424/)
5.  Parsa A, Kao WHL, Xie D, et al. APOL1 risk variants, race, and progression of chronic kidney disease. *N Engl J Med.* 2013;369(23):2183–2196. [PMID: 24206458](https://pubmed.ncbi.nlm.nih.gov/24206458/)
6.  Bidani AK, Griffin KA. Pathophysiology of hypertensive renal damage: implications for therapy. *Hypertension.* 2004;44(5):595–601. [PMID: 15452024](https://pubmed.ncbi.nlm.nih.gov/15452024/)
7.  Schiffrin EL, Deng LY, Larochelle P. Effects of a beta-blocker or a converting enzyme inhibitor on resistance arteries in essential hypertension. *Hypertension.* 1994;23(1):83–91. [PMID: 8282334](https://pubmed.ncbi.nlm.nih.gov/8282334/)
8.  Griffin KA, Polichnowski A, Litbarg N, et al. Critical blood pressure threshold dependence of hypertensive injury and repair in a malignant nephrosclerosis model. *Hypertension.* 2014;64(4):801–807. [PMID: 24958497](https://pubmed.ncbi.nlm.nih.gov/24958497/)

Adapted from the Clinical Mastery review "Hypertensive Nephropathy: Incidence, Nosology & the Autoregulation Paradox." [Read the full physician-level review →](https://urinenephrology.org/mastery/hypertension-advanced/hypertensive-nephropathy.html)

📚 For Educational Purposes Only

© 2026 Andrew Bland, MD, FACP, FAAP - All Rights Reserved

### Also on this topic

The same subject at other levels of depth.

- **Clinical Mastery deep dive:** [Hypertensive Nephropathy](https://urinenephrology.org/mastery/hypertension-advanced/hypertensive-nephropathy.html)


---

[Website version](https://urinenephrology.org/2025_UDPA_Lectures_Live/hypertension/hypertensive-nephropathy.html) · Markdown synchronized October 3, 2026.